Conjugating antibodies to cytotoxic agents: getting the best of both worlds?
Anna
A
Azvolinsky
D000080044:Ado-Trastuzumab Emtansine; D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000378:metabolism; D000079963:Brentuximab Vedotin; D003603:Cytotoxins / Q000009:adverse effects* / Q000378:metabolism; D006801:Humans; D018796:Immunoconjugates / Q000494:pharmacology; D000922:Immunotoxins / Q000276:immunology / Q000494:pharmacology*; D008453:Maytansine / Q000031:analogs & derivatives / Q000494:pharmacology; D000068878:Trastuzumab
D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D003603:Cytotoxins; D018796:Immunoconjugates; D000922:Immunotoxins; D008453:Maytansine; D000079963:Brentuximab Vedotin; D000068878:Trastuzumab; D000080044:Ado-Trastuzumab Emtansine